The present and the future landscape of treatment of advanced hepatocellular carcinoma

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages S273-S280

  Rimassa, Lorenza ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Advanced hepatocellular carcinoma; Molecularly targeted therapies; Sorafenib

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; LAPATINIB; OXALIPLATIN; PLACEBO; SORAFENIB; SUNITINIB; UFT; VATALANIB; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOICE CHANGE; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; DRUG DESIGN; LIVER NEOPLASMS; PATHOLOGY; SURVIVAL;

BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DRUG DESIGN; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; SURVIVAL ANALYSIS;

EID: 77953689504     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60516-6     Document Type: Article

References (40)

1. Zhu AX Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?. Oncologist 2006, 11:790-800.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
3. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
4. Keating GM, Santoro A Sorafenib. A review of its use in hepatocellular carcinoma. Drugs 2009, 69:1-17.
5. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293-4300.
6. Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009, 9:208.
7. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Nati Cancer Inst 2008, 100:698-711.
8. Rimassa L, Santoro A Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther 2009, 9:739-745.
9. Personeni N, Bozzarelli S, Giordano L, et al. Serial alpha-fetoprotein evaluation and survival in hepatocellular carcinoma patients treated with sorafenib. Eur J Cancer 2009, 7:394. (abstr. 6616).
10. Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009, 14:70-76.
11. Worns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009, 43:489-495.
12. Abou-alfa GK, Johnson P, Knox J, et al. Final results from a phase II (Phil), randomized, double-blind study of sorafenib plus doxoru-bicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). 2008 Gastrointestinal Cancer Symposium. Orlando (El), USA, 25-27 January 2008 (abstr. 128).
13. Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 2009, 45:579-587.
14. Shen Y, Hsu C, Hsu C, et al. A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2009, 27:223s. (abstr. 4589).
15. Petrini I, Lencioni M, Ricasoli M, et al. A phase II (Phil) study of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (ci.) in patients with advanced hepatocellular carcinoma (HCC): preliminary data. J Clin Oncol 2009, 27:224s. (abstr. 4592).
16. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005, 23:6657-6663.
17. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007, 110:1059-1067.
18. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008, 26:2992-2998.
19. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcita-bine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:1898-1903.
20. Hsu C, Yang T, Hsu C, et al. Modified-dose capecitabine + bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study. J Clin Oncol 2007, 25:649s. (abstr. 15190).
21. Sun W, Haller DG, Mykulowicz K, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study. J Clin Oncol 2007, 25:216s. (abstr. 4574).
22. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009, 27:843-850.
23. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27:3027-3035.
24. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009, 10:794-800.
25. Ramanathan RK, Belani CP, Singh DA, et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol 2006, 24:181s. (abstr. 4010).
26. Bekaii-Saab T, Markowitz J, Prescott N, et al. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2009, 15:5895-5901.
27. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of ce-tuximab in patients with advanced hepatocellular carcinoma. Cancer 2007, 110:581-589.
28. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin-(GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008, 112:2733-2739.
29. Raoul JL, Fin RS, Kang YK, et al. An open label phase II study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2009, 27:221s. (abstr. 4577).
30. Kanai K, Yoshida H, Tateishi R, et al. Final result of a phase I/II trial of the oral anti-angiogenesis inhibitor TSU-68 in patients with advanced hepatocellular carcinoma. J Clin Oncol 2008, 26:235s. (abstr. 4589).
31. Alberts SR, Morlan BW, Kim GR, et al. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC) -Interim review of toxicity. 2007 Gastrointestinal Cancer Symposium. Orlando (Fl), USA, 19-21 January 2007 (abstr. 186).
32. Koch I, Baron A, Roberts S, et al. Influence of Hepatic Dysfunction on Safety, Tolerability, and Pharmacokinetics (PK) of PTK787/ZK 222584 in Patients (Pts) with Unresectable Hepatocellular Carcinoma (HCC). J Clin Oncol 2005, 23:341s. (abstr. 4134).
33. Toh H, Chen P, Carr BI, et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis. J Clin Oncol 2009, 27:222s. (abstr. 4581).
34. Santoro A, Citterio G, Pressiani T, et al. Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC). Eur J Cancer 2009, 7:395. (abstr. 6617).
35. Chen L, Shiah HS, Chen CY, et al. Randomized, phase I, and phar-macokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2009, 27:223s. (abstr. 4587).
36. Uhm JE, Park JO, Lee J, et al. A phase II study of oxaliplatin in combination with doxorabicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009, 63:929-935.
37. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007, 109:1384-1390.
38. Lee JO, Lee KW, Oh DY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 2009, 20:1402-1407.
39. Edeline J, Raoul JL, Vauleon E, et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroenterol 2009, 15:713-716.
40. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologie response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009, 27:446-452.